Keros Therapeutics, Inc. (KROS) company profile
Close on Nov 17, 2026Market cap $224.25MP/E –Yield –
About Keros Therapeutics
Pharmaceutical Preparations, SIC 2834
The company is a clinical-stage biopharmaceutical organization focused on discovering, developing, and commercializing novel protein therapeutics for disorders linked to dysfunctional transforming growth factor-beta (TGF-ß) signaling pathways. Its pipeline centers on engineered ligand traps designed to target tissues such as skeletal muscle, bone, adipose tissue, and blood. The primary product candidate, rinvatercept, targets neuromuscular conditions including Duchenne muscular dystrophy and amyotrophic lateral sclerosis. Its other key candidate, elritercept, addresses cytopenias such as anemia and thrombocytopenia in patients with myelodysplastic syndromes and myelofibrosis. The company aims to serve patient populations suffering from rare neuromuscular and hematological disorders.
Operating as a development-stage biopharmaceutical enterprise, the company conducts preclinical studies and clinical trials, including global collaborative partnerships. It has established an exclusive licensing agreement covering the worldwide development, manufacturing, and commercialization of elritercept outside of mainland China, Hong Kong, and Macau. The provided excerpt does not disclose the company's specific headquarters location or physical facility count.
Summary of the business section of Keros Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Keros Therapeutics, Inc.
- Headquarters
- Lexington, MA
- Address
- 1050 Waltham Street, Suite 302 02421
- Phone
- (617) 314-6297
- Website
- kerostx.com
- Employees
- 78, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Boston, MA
Stock & identifiers
- Ticker
- KROS
- Exchange
- Nasdaq
- IPO date
- Apr 8, 2020
- Shares outstanding
- 20M, Jul 27, 2026
- Public float
- $453.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1664710
- CUSIP
- 492327101
- ISIN
- US4923271013
- FIGI
- BBG00H1HP9G9
- Share class FIGI
- BBG00H1HP9H8
- EIN
- 81-1173868
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jasbir Seehra | CHIEF EXECUTIVE OFFICER, Director | 440,708 |
| Lorena Raquel Lerner | Chief Scientific Officer | 27,559 |
| Annita Tanini | Corp. Controller & VP, Finance | 45,144 |
| Esther Cho | Chief Legal Officer | 35,770 |
| Keith Regnante | CHIEF FINANCIAL OFFICER | 39,261 |
| Yung H. Chyung | Chief Medical Officer | 44,000 |
| Christopher Rovaldi | Chief Operating Officer | 60,000 |
| Anne Prener | Director | 13,212 |
| Charles W. Newton | Director | 12,114 |
| Jean Jacques Bienaime | Director | 19,592 |
| Nima Farzan | Director | 9,767 |
| Julius Knowles | Director | 161,005 |
| Mary Ann Gray | Director | 12,392 |
| Alpna Seth | Director | 12,392 |
| Carl L. Gordon | Director | 764,405 |
| Genesis GP LLC OrbiMed | Director | 45,057 |
| Capital GP VII LLC OrbiMed | Director | 148,922 |
| Advisors Llc Orbimed | Director | – |
| Ran Nussbaum | Director | 160,512 |
| Tomer Kariv | Director | 160,512 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $2.54M | $3.71M | $1.23M | $29 | – |
| FY2024 | $6.27M | $2.70M | $4.17M | $22 | – |
| FY2023 | $8.93M | $3.44M | $3.04M | $56 | – |
| FY2022 | $6.46M | $710.05K | $3.28M | $68 | $90 |
| FY2021 | $7.23M | -$4.45M | $2.88M | $83 | $100 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Jasbir Seehra President and Chief Executive Officer | $700.00K | $1.43M | $398.13K | $15.80K | $2.54M | -60% |
| Keith Regnante Chief Financial Officer | $470.38K | $464.64K | $164.85K | $14.00K | $1.11M | -51% |
| Esther Cho Chief Legal Officer | $459.19K | $464.64K | $161.00K | $14.00K | $1.10M | – |
| Christopher Rovaldi Former President and Chief Operating Officer | $578.92K | $871.20K | – | $25.99K | $1.48M | -79% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Apr 8, 2020
- Offer price
- $16.00
- Securities offered
- 6,000,000
- Gross proceeds
- $96.00M
- Exchange
- Nasdaq
- First trading day
- Apr 8, 2020
- First-day close
- $20.08+25.5%
- Lock-up ends (est.)
- Oct 5, 2020
“The initial public offering price is $16.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 78 full-time employees, including 27 who hold Ph.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 10, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
| Apr 8, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 3, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?